New registry explores targeted drug combos for hard-to-treat pancreatic cancer
Knowledge-focused
Recruiting now
This observational study tracks 80 people with advanced pancreatic cancer that has a specific genetic change called KRAS G12R. Participants receive one of three treatment plans: a MEK inhibitor combined with other drugs, with or without hydroxychloroquine or an EGFR inhibitor. Th…
Sponsor: Mandana Kamgar, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC